1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Bladder cancer

Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

Awaiting development [GID-TA11517] Expected publication date: TBC

  • Project information
  • Project documents

33623-Durvalumab-Enfortumab-Vedotin-or-Tremelimumab-for-Muscle-Invasive-Bladder-Cancer-V1.0-JAN2024-NON-CONF.pdf (nihr.ac.uk)